148 related articles for article (PubMed ID: 36621781)
1. The roles of IDH1 in tumor metabolism and immunity.
Ni Y; Shen P; Wang X; Liu H; Luo H; Han X
Future Oncol; 2022 Nov; 18(35):3941-3953. PubMed ID: 36621781
[TBL] [Abstract][Full Text] [Related]
2. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.
Dang L; White DW; Gross S; Bennett BD; Bittinger MA; Driggers EM; Fantin VR; Jang HG; Jin S; Keenan MC; Marks KM; Prins RM; Ward PS; Yen KE; Liau LM; Rabinowitz JD; Cantley LC; Thompson CB; Vander Heiden MG; Su SM
Nature; 2009 Dec; 462(7274):739-44. PubMed ID: 19935646
[TBL] [Abstract][Full Text] [Related]
3. Metabolic consequences of oncogenic IDH mutations.
Parker SJ; Metallo CM
Pharmacol Ther; 2015 Aug; 152():54-62. PubMed ID: 25956465
[TBL] [Abstract][Full Text] [Related]
4. Mutant IDH1 enhances the production of 2-hydroxyglutarate due to its kinetic mechanism.
Rendina AR; Pietrak B; Smallwood A; Zhao H; Qi H; Quinn C; Adams ND; Concha N; Duraiswami C; Thrall SH; Sweitzer S; Schwartz B
Biochemistry; 2013 Jul; 52(26):4563-77. PubMed ID: 23731180
[TBL] [Abstract][Full Text] [Related]
5. Isocitrate dehydrogenase gene mutations and 2-hydroxyglutarate accumulation in esophageal squamous cell carcinoma.
Miyake K; Baba Y; Ishimoto T; Hiyoshi Y; Iwatsuki M; Miyamoto Y; Yoshida N; Watanabe M; Ogata Y; Nagayama M; Silsirivanit A; Kobayashi D; Araki N; Baba H
Med Oncol; 2018 Nov; 36(1):11. PubMed ID: 30506321
[TBL] [Abstract][Full Text] [Related]
6. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.
Gross S; Cairns RA; Minden MD; Driggers EM; Bittinger MA; Jang HG; Sasaki M; Jin S; Schenkein DP; Su SM; Dang L; Fantin VR; Mak TW
J Exp Med; 2010 Feb; 207(2):339-44. PubMed ID: 20142433
[TBL] [Abstract][Full Text] [Related]
7. Increased mitochondrial activity in a novel IDH1-R132H mutant human oligodendroglioma xenograft model: in situ detection of 2-HG and α-KG.
Navis AC; Niclou SP; Fack F; Stieber D; van Lith S; Verrijp K; Wright A; Stauber J; Tops B; Otte-Holler I; Wevers RA; van Rooij A; Pusch S; von Deimling A; Tigchelaar W; van Noorden CJ; Wesseling P; Leenders WP
Acta Neuropathol Commun; 2013 May; 1():18. PubMed ID: 24252742
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms of isocitrate dehydrogenase 1 (IDH1) mutations identified in tumors: The role of size and hydrophobicity at residue 132 on catalytic efficiency.
Avellaneda Matteo D; Grunseth AJ; Gonzalez ER; Anselmo SL; Kennedy MA; Moman P; Scott DA; Hoang A; Sohl CD
J Biol Chem; 2017 May; 292(19):7971-7983. PubMed ID: 28330869
[TBL] [Abstract][Full Text] [Related]
9. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
Ward PS; Patel J; Wise DR; Abdel-Wahab O; Bennett BD; Coller HA; Cross JR; Fantin VR; Hedvat CV; Perl AE; Rabinowitz JD; Carroll M; Su SM; Sharp KA; Levine RL; Thompson CB
Cancer Cell; 2010 Mar; 17(3):225-34. PubMed ID: 20171147
[TBL] [Abstract][Full Text] [Related]
10. Hyperpolarized [1-13C] glutamate: a metabolic imaging biomarker of IDH1 mutational status in glioma.
Chaumeil MM; Larson PE; Woods SM; Cai L; Eriksson P; Robinson AE; Lupo JM; Vigneron DB; Nelson SJ; Pieper RO; Phillips JJ; Ronen SM
Cancer Res; 2014 Aug; 74(16):4247-57. PubMed ID: 24876103
[TBL] [Abstract][Full Text] [Related]
11. Isocitrate dehydrogenase variants in cancer - Cellular consequences and therapeutic opportunities.
Liu S; Cadoux-Hudson T; Schofield CJ
Curr Opin Chem Biol; 2020 Aug; 57():122-134. PubMed ID: 32777735
[TBL] [Abstract][Full Text] [Related]
12. Targeting isocitrate dehydrogenase (IDH) in cancer.
Fujii T; Khawaja MR; DiNardo CD; Atkins JT; Janku F
Discov Med; 2016 May; 21(117):373-80. PubMed ID: 27355333
[TBL] [Abstract][Full Text] [Related]
13. Development of Novel Therapeutics Targeting Isocitrate Dehydrogenase Mutations in Cancer.
Sharma H
Curr Top Med Chem; 2018; 18(6):505-524. PubMed ID: 29773061
[TBL] [Abstract][Full Text] [Related]
14. Cancer-associated isocitrate dehydrogenase 1 (IDH1) R132H mutation and d-2-hydroxyglutarate stimulate glutamine metabolism under hypoxia.
Reitman ZJ; Duncan CG; Poteet E; Winters A; Yan LJ; Gooden DM; Spasojevic I; Boros LG; Yang SH; Yan H
J Biol Chem; 2014 Aug; 289(34):23318-28. PubMed ID: 24986863
[TBL] [Abstract][Full Text] [Related]
15. Mutation of
Su L; Zhang X; Zheng L; Wang M; Zhu Z; Li P
Front Endocrinol (Lausanne); 2020; 11():189. PubMed ID: 32373065
[No Abstract] [Full Text] [Related]
16. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability.
Wise DR; Ward PS; Shay JE; Cross JR; Gruber JJ; Sachdeva UM; Platt JM; DeMatteo RG; Simon MC; Thompson CB
Proc Natl Acad Sci U S A; 2011 Dec; 108(49):19611-6. PubMed ID: 22106302
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanisms of "off-on switch" of activities of human IDH1 by tumor-associated mutation R132H.
Yang B; Zhong C; Peng Y; Lai Z; Ding J
Cell Res; 2010 Nov; 20(11):1188-200. PubMed ID: 20975740
[TBL] [Abstract][Full Text] [Related]
18. Isocitrate dehydrogenase mutations in gliomas.
Waitkus MS; Diplas BH; Yan H
Neuro Oncol; 2016 Jan; 18(1):16-26. PubMed ID: 26188014
[TBL] [Abstract][Full Text] [Related]
19. Identification and Characterization of Small-Molecule Inhibitors of the R132H/R132H Mutant Isocitrate Dehydrogenase 1 Homodimer and R132H/Wild-Type Heterodimer.
Brooks E; Wu X; Hanel A; Nguyen S; Wang J; Zhang JH; Harrison A; Zhang W
J Biomol Screen; 2014 Sep; 19(8):1193-200. PubMed ID: 24980596
[TBL] [Abstract][Full Text] [Related]
20. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha.
Zhao S; Lin Y; Xu W; Jiang W; Zha Z; Wang P; Yu W; Li Z; Gong L; Peng Y; Ding J; Lei Q; Guan KL; Xiong Y
Science; 2009 Apr; 324(5924):261-5. PubMed ID: 19359588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]